Threshold starts dosing in Phase I/II trial of myeloma combination drug TH-302/Bortezomib
In the dose-escalation and dose-expansion stages of the trial assesing TH-302 and low-dose dexamethasone without bortezomib, patients were heavily-pretreated, and objective responses were observed in 5/16 patients treated